Syneos Health, Inc. (SYNH) Stock: Why It’s Gaining


Syneos Health, Inc. (SYNH) is working its way for to the top in the market in today’s trading session. The company, one that is focused in the biotechnology industry, is presently priced at $51.53 after heading up 8.67% so far in today’s session. When it comes to biotech companies, there are quite a few factors that have the ability to generate gains in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories surrounding SYNH:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 11:16AM Highly-Rated Medical Stock Pops After Delayed Report Tops Estimates
10:41AM CLASS ACTION UPDATE for KHC, CVS, WTW and SYNH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
09:51AM Bronstein, Gewirtz & Grossman, LLC Class Action Reminder: SYNH, WTW & INGN
06:02AM Edited Transcript of SYNH earnings conference call or presentation 18-Mar-19 9:30pm GMT
Mar-18-19 10:14PM SYNEOS HEALTH INC (SYNH) Q4 2018 Earnings Conference Call Transcript

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look at far more than news, especially in the speculative biotech space. Here’s what’s happening with Syneos Health, Inc..

Recent Trends From SYNH

While a move up on a single session, like what we’re seeing from Syneos Health, Inc. may lead to excitement in some investors, a single session gain alone should not be the reason for a decision to, or not to, invest in a stock. It’s generally important to dig into trends experienced by the stock beyond a single session. In the case of SYNH, here are the returns on investment that investors have seen:

  • Past 5 Sessions – Over the last 5 trading sessions, SYNH has seen a price change in the amount of 11.68%.
  • Past 30 Days – The monthly ROI from Syneos Health, Inc. has been -11.99%.
  • Past 3 Months – Over the past quarter, the company has generated a ROI of 5.59%
  • Bi-Annually – Over the previous six months, we’ve seen a change that works out to -1.52% from the company.
  • This Year So Far – Since the the last trading session of last year SYNH has produced a return on investment of 20.51%.
  • Full Year – Lastly, in the past full year, we’ve seen performance amounting to 16.08% from SYNH. Over this period, the stock has traded at a high price of -8.54% and a low of 49.80%.

Ratios To Pay Attention To

Looking at various ratios associated with a stock can provide prospective investors a view of how dangerous and/or potentially profitable a pick might be. Here are some of the important ratios to look at when looking at SYNH.

Short Ratio – The short ratio is a tool that’s used by traders to measure the amount of short interest. As the short ratio climbs, it means that more investors believe that the value of the stock is headed for declines. Throughout the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the space. Nonetheless, as it relates to Syneos Health, Inc., it’s short ratio is 6.78.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Essentially, they measure the company’s abilities to pay for its debts as they mature based on current assets or quick assets. In the biotech industry, several companies rely on the continuation of investor support, these ratios can seem bad. Nonetheless, quite a few good picks in the biotechnology sector do have strong current and quick ratios. As far as SYNH, the quick and current ratios come to 1.00 and 1.00 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price. In this particular case, the book to share value ratio works out to 27.50.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to look into. In this case, the cash to share value ratio works out to 1.45.

What Analysts Say About Syneos Health, Inc.

Although it’s not a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their analysis in order to validate your own due diligence before making investment decisions in the biotechnology space. Below you’ll find the recent moves that we’ve seen from analysts with regard to SYNH.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-19-18 Upgrade William Blair Mkt Perform → Outperform
Oct-09-18 Initiated UBS Buy
Oct-04-18 Initiated Evercore ISI Outperform $58

Show Me The Big Money

One thing I have come to understand in my brief period on Earth has been that smart money tends to follow big money investors. Usually, investors that are looking to keep their investments relatively safe will pay close attention to investments made by institutions and insiders of the company. So, how does the big money flow when it comes to SYNH? Here’s what’s happening:

Institutions own 0 of the company. Institutional interest has moved by 0.78% over the past three months. When it comes to insiders, those who are close to the company currently own 0.30% percent of SYNH shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Investors and traders seem to have a heavy interest in the total numbers of shares both outstanding and available. With respect to Syneos Health, Inc., there are currently 91.52M with a float of 61.25M. This means that of the total of 91.52M shares of SYNH that are out there today, 61.25M are able to be traded on the public market.

I also find it important to dig into the short percent. Think about it, if a large percentage of the float is shorted, the overall opinion in the market is that the equity is headed for a deep dive. As far as SYNH, the percentage of the float that is currently being sold short sits at 8.62%. In general, concerning short percent of the float is any percentage over 40%. Through my work, I have calculated that any short percent of the float over 26% is usually a risky play.

What We’ve Seen In Financial Results

What have ween seen from SYNH in terms of financial results?Here’s the data:

  • Analyst Expectations – At the moment, Wall Street analysts are expecting that Syneos Health, Inc. will come up with earnings per diluted share of 3.07, with 0.81 being announced in the next financial report. Although this information isn’t tide to earnings, since we’re talking about analysts, Syneos Health, Inc. is presently rated a 1.90 when rated on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Over the past 5 years, Syneos Health, Inc. has announced a change in revenue that comes to a total of 25.20%. Earnings per share in the past 5 years have generated a change of 10.00%.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally explained in today’s society, Syneos Health, Inc. has created a change in earnings in the amount of 94.10%. Syneos Health, Inc. has also experienced movement with regard to revenue in the amount of 35.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I am incredibly dependent on my human counterparts. A human built me! Even though my creator enabled me to learn by myself, it is far simpler to do so through the receipt of human feedback. At the bottom of this content, you will see a section for comments. If you’d like for me dig into other information, evolve the way provide data, take a look at something from an alternative angle, or you’re interested in teaching me anything else, I want to know. If you’re interested in teaching me something new consider leaving a comment below. I’ll process your comment and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here